Title	**Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines**
Authors	Nicholas A Kennedy, PhD[1,2]*, Simeng Lin, MBChB[1,2]*, James R Goodhand, MBBS[1,2]*, Neil Chanchlani, MBChB[1,2], Ben Hamilton MBBS[1,2], Claire Bewshea, MSc[2], Rachel Nice, MSc[2,3], Desmond Chee, MBBS[1,2], JR Fraser Cummings, DPhil[4], Aileen Fraser, MSc[5], Peter M Irving, MD[6,7], Nikolaos Kamperidis, MD[8], Klaartje B Kok, PhD[9,10], Christopher A Lamb, PhD[11,12], Jonathan Macdonald, BM[13,14], Shameer J Mehta, MD[15], Richard CG Pollok, PhD[16,17], Tim Raine, PhD[18], Philip J Smith, MBBS[19], Ajay M Verma, MD[20], Timothy J McDonald, PhD[2,3], Shaji Sebastian, MD[21, 22], Charlie W Lees, PhD[23,24], Nick Powell, PhD[25,26]*, Tariq Ahmad, DPhil[1,2]*, Contributors to the CLARITY IBD study *denotes equal contribution
Affiliations	[1] Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK [2] Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, UK [3] Department of Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK [4] Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK [5] Department of Gastroenterology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK [6] Department of Gastroenterology, Guy's and St Thomas' NHS

Foundation Trust, London, UK

[7]School of Immunology & Microbial Sciences, King's College London, London, UK

[8] Department of Gastroenterology, St Marks Hospital and Academic Institute, London, UK

[9] Centre for Immunobiology, Blizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK

[10] Department of Gastroenterology, Royal London Hospital, Barts Health NHS Trust, London, UK

[11] Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

[12] Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

[13] Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK

[14] School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK

[15] Department of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK

[16] Department of Gastroenterology, St George's University Hospital NHS Foundation Trust, London, UK

[17] Institute for Infection & Immunity, St George's, University of London, London, UK

[18] Department of Gastroenterology, Addenbrooke's Hospital, Cambridge

University Hospitals NHS Foundation Trust, Cambridge, UK

[19] Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

[20] Department of Gastroenterology, Kettering General Hospital, Kettering, UK

[21] IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK

[22] Hull York Medical School, University of Hull, Hull, UK

[23] Department of Gastroenterology, Western General Hospital, NHS Lothian, Edinburgh, UK

[24] Institute of Genetic and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Gastroenterology, Western General Hospital, Edinburgh, UK

[25] Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK

[26] Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK

Address for correspondence	Prof Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK tariq.ahmad1@nhs.net
Key words	SARS-CoV-2, immune-mediated inflammatory diseases, inflammatory bowel disease, anti-TNF therapy, infliximab, vedolizumab, immunosuppressant, vaccine, ChAdOx1 nCoV-19, BNT162b2, CLARITY
Running title	
Word count	2939

2   **Research in context**

Evidence before this study

Faced with further surges of SARS-CoV-2 infection, a growing number of countries, including the UK,

have opted to delay second vaccine doses for all people. This strategy trades maximal effectiveness

against a lower level of protective immunity across more of the at-risk population.

We have previously shown that seroprevalence, seroconversion in PCR-confirmed cases, and the

magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab-

compared with vedolizumab-treated patients. Whether single-doses of vaccines are effective in

patients treated with anti-TNF therapies is unknown.

We searched PubMed from 25 November 2019 to 23 March 2021 with the terms "anti-tumour

necrosis factor" or "anti-integrin" or "infliximab" or "adalimumab" or "vedolizumab" or "biological

therapy" or "biologic therapy" AND "SARS-CoV-2" or "coronavirus" or "COVID-19" or AND

"seroprevalence" or "seroconversion" or "antibody" or "antibody response" or "magnitude" or

"immunogenicity" AND "vaccine" or "vaccination" or "immunisation" or "immunization" or

"ChAdOx1 nCoV-19" or "BNT162b2" or "mRNA-1273", without restriction on language.

Serological responses to SARS-CoV-2 vaccines have been reported in registration trials and small

observational cohorts of healthy volunteers. Two small studies, including one unpublished preprint,

found that COVID-19 vaccine immunogenicity rates were lower in transplant recipients and patients

with malignancy receiving immunosuppressive therapy, and fewer patients treated with potent

immunosuppressants seroconverted than healthy controls. No studies have assessed the effect of

anti-TNF therapy on immunogenicity following SARS-CoV-2 vaccination.

Added value of this study

To test if anti-TNF drugs attenuate serological responses to primary SARS-CoV-2 vaccines, we

analysed anti-SARS-CoV-2 spike (S) antibody concentrations and seroconversion rates in 1293

patients with inflammatory bowel disease who received primary vaccinations with either the

ChAdOx1 nCoV-19 or BNT162b2 vaccines. 865 were treated with the anti-TNF drug infliximab and

outcomes were compared to a reference cohort of 428 patients treated with vedolizumab, a gut

selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired systemic

immune responses.

Anti-SARS-CoV-2 antibody levels and rates of seroconversion were lower following primary

vaccination with both the BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD treated

with infliximab compared to vedolizumab. Older age, immunomodulator use, Crohn's disease

(versus ulcerative colitis or inflammatory bowel disease unclassified), and current smoking were

associated with lower anti-SARS-CoV-2 antibody concentrations, irrespective of vaccine type. Non-

white ethnicity was associated with higher anti-SARS-CoV-2 (S) antibody concentrations following

primary vaccination with both vaccines. Antibody concentrations and seroconversion rates were

higher in patients with past SARS-CoV-2 infection prior to a single-dose of either vaccine, and after 2

doses of the BNT162b2 vaccine.

Implications of the available evidence

Our findings have important implications for patients treated with anti-TNF therapy, particularly for

those also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine

exposes these patients to a potential increased risk of SARS-CoV-2 infection. However, higher rates

of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even in the presence of

TNF blockade, suggest that all patients receiving these drugs should be prioritized for optimally

timed second doses. Until patients receive a second vaccine dose, they should consider that they are

not protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and

shielding if appropriate. Even after two antigen exposures, a small subset of patients failed to mount

an antibody response. Antibody testing and adapted vaccine schedules should be considered to

protect these at-risk patients.

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

Abstract

Background

Delayed second-dose SARS-CoV-2 vaccination trades maximal effectiveness for a lower level of

immunity across more of the population. We investigated whether patients with inflammatory

bowel disease treated with infliximab have attenuated serological responses to a single-dose of a

SARS-CoV-2 vaccine.

Methods

Antibody responses and seroconversion rates in infliximab-treated patients (n=865) were compared

to a cohort treated with vedolizumab (n=428), a gut-selective anti-integrin α4β7 monoclonal

antibody. Our primary outcome was anti-SARS-CoV-2 spike (S) antibody concentrations 3-10 weeks

after vaccination in patients without evidence of prior infection. Secondary outcomes were

seroconversion rates, and antibody responses following past infection or a second dose of the

BNT162b2 vaccine.

Findings

Geometric mean [SD] anti-SARS-CoV-2 antibody concentrations were lower in patients treated with

infliximab than vedolizumab, following BNT162b2 (6·0 U/mL [5·9] vs 28·8 U/mL [5·4] P<0·0001) and

ChAdOx1 nCoV-19 (4·7 U/mL [4·9]) vs 13·8 U/mL [5·9] P<0·0001) vaccines. In our multivariable

models, antibody concentrations were lower in infliximab- compared to vedolizumab-treated

patients who received the BNT162b2 (fold change [FC] 0·29 [95% CI 0·21, 0·40], p<0·0001) and

ChAdOx1 nCoV-19 (FC 0·39 [95% CI 0·30, 0·51], p<0·0001) vaccines. In both models, age ≥ 60 years,

immunomodulator use, Crohn's disease, and smoking were associated with lower, whilst non-white

ethnicity was associated with higher, anti-SARS-CoV-2 antibody concentrations. Seroconversion

rates after a single-dose of either vaccine were higher in patients with prior SARS-CoV-2 infection

and after two doses of BNT162b2 vaccine.

Interpretation

Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and

ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. Vaccination after SARS-CoV-2 infection, or a second dose of

vaccine, led to seroconversion in most patients. Delayed second dosing should be avoided in

patients treated with infliximab.

Funding

Introduction

Limited SARS-CoV-2 vaccine supplies and pressure on critical care services have forced governments to prioritise primary vaccination to vulnerable groups. In the United Kingdom, second vaccine doses have also been delayed, trading maximal effectiveness for a lower level of protective immunity across a greater proportion of the most at-risk population.[1] Consequently, more than half of the adult population have received a single-dose of either the RNA vaccine, BNT162b2 (Pfizer/BioNTech) or the adenovirus-vector vaccine, ChAdOx1 nCoV-19 (Oxford/AstraZeneca). Faced with further surges of SARS-CoV-2 infection, a growing number of other countries have also opted to delay second vaccine doses.[2,3]

The inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis (UC) are chronic immune-mediated inflammatory diseases (IMIDs) that affect about 1% of the UK population.[4,5] Treatment typically requires immunosuppression with immunomodulators (azathioprine, mercaptopurine, and methotrexate) and/or biological therapies that target disease relevant cytokines or the immune cells that produce them. Anti-tumour necrosis factor (TNF) drugs, such as infliximab and adalimumab, are the most frequently prescribed biopharmaceuticals used in the treatment of IMIDs. These drugs impair immunogenicity following pneumococcal,[6] influenza,[7] and hepatitis B[8] vaccinations and increase the risk of serious infection, most notably with respiratory pathogens.[9] Conversely, vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody is not associated with increased susceptibility to systemic infection or attenuated serological responses to vaccination.[10]

We have recently reported that seroprevalence, seroconversion in PCR-confirmed cases, and the magnitude of anti-SARS-CoV-2 antibodies following SARS-CoV-2 infection are reduced in infliximab-compared with vedolizumab-treated patients.[11] We hypothesised that, following at least a single-dose with BNT162b2 or ChAdOx1 nCoV-19 vaccine, serological responses would be similarly

impaired in patients treated with infliximab compared to vedolizumab arguing against delaying

second doses in these patients.

We aimed to define, in patients with IBD who had received a COVID-19 vaccination, whether biologic

class and concomitant use of an immunomodulator impact:

i)   anti-SARS-CoV-2 spike (S) antibody levels

ii)   rates of seroconversion

iii)   antibody responses in patients who had previously been infected with SARS-CoV-2 or who

118   had two doses of vaccine

Methods

Study design and participants

impaCt of bioLogic therApy on saRs-cov-2 Infection and immuniTY (CLARITY) IBD is a UK wide, multicentre, prospective observational cohort study investigating the impact of infliximab and vedolizumab and/or concomitant immunomodulators (azathioprine, mercaptopurine, and methotrexate) on SARS-CoV-2 acquisition, illness, and immunity in patients with IBD.

Study methods have been described in detail previously.[11] In brief, consecutive patients were recruited at the time of attendance at infusion units from 92 National Health Service (NHS) hospitals across the UK between 22nd September 2020 and 23rd December 2020 (Supplementary pp 2 - 17). The eligibility criteria were age 5 years and over, a diagnosis of IBD, and current treatment with infliximab or vedolizumab for 6 weeks or more, with at least one dose of drug received in the previous 16 weeks. Patients were excluded if they had participated in a SARS-CoV-2 vaccine trial.

Follow-up visits were timed to coincide with biologic infusions and occurred approximately eight-weekly. Here, we report vaccine-induced antibody responses at first study visit after primary vaccination, and where possible, after two doses. Participants were eligible for inclusion in our vaccine immunogenicity analysis if they had had a SARS-CoV-2 antibody test within the first ten weeks after their primary vaccination with any of the available SARS-CoV-2 vaccines.

The Surrey Borders Research Ethics committee approved the study (REC reference: 20/HRA/3114) in September 2020. Patients were included after providing informed, written consent. The sponsor was the Royal Devon and Exeter NHS Foundation Trust. The protocol is available online at https//www.clarityibd.org. The study was registered with the ISRCTN registry, ISRCTN45176516.

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

Procedures

Variables recorded by participants were demographics (age, sex, ethnicity, comorbidities, height and

weight, smoking status, and postcode), IBD disease activity (PRO2), SARS-CoV-2 symptoms aligned to

the COVID-19 symptoms study (symptoms, previous testing, and hospital admissions for COVID-19),

and vaccine uptake (type and date of primary vaccination). Study sites completed data relating to

IBD history (age at diagnosis, disease duration, and phenotype according to the Montreal

classifications, previous surgeries, and duration of current biologic and immunomodulator

therapy).[11] We linked our data by NHS number or Community Health Index to Public Health England,

Scotland, and Wales who archive dates and results of all SARS-CoV-2 PCR tests undertaken. Data

were entered electronically into a purpose-designed REDCap database hosted at the Royal Devon

and Exeter NHS Foundation Trust.[12] Participants without access to the internet or electronic device

completed their questionnaires on paper case record forms that were subsequently entered by local

research teams.

Laboratory analyses were performed at the Academic Department of Blood Sciences at the Royal

Devon and Exeter NHS Foundation Trust. To determine antibody responses specific to vaccination

we used the Roche Elecsys Anti-SARS-CoV-2 spike (S) immunoassay[13] alongside the nucleocapsid (N)

immunoassay.[14] This double sandwich electrochemiluminescence immunoassay uses a recombinant

protein of the receptor binding domain on the spike protein as an antigen for the determination of

antibodies against SARS-CoV-2. Sample electrochemiluminescence signals are compared to an

internal calibration curve and quantitative values are reported as units (U)/mL.

In-house assay validation experiments demonstrated:

i) The intra-assay and inter-assay coefficient of variation were 1·3% and 5·6%, respectively

ii) Anti-SARS-CoV-2 (S) antibodies were stable in uncentrifuged blood and serum at ambient

temperature for up to seven days permitting postal transport

iii) No effect was observed on recovery of anti-SARS-CoV-2 (S) antibodies following four

freeze/thaw cycles

iv) No analytical interference was observed for the detection of anti-SARS-CoV-2 (S) with

infliximab or vedolizumab up to 10,000 mg/L and 60,000 mg/L, respectively, or with anti-

drug antibodies to infliximab or vedolizumab up to 400 AU/mL and 38 AU/mL, respectively

(data not shown).

At entry to CLARITY IBD and at follow-up visits, all patients were tested for previous SARS-CoV-2

infection using the Roche Elecsys anti-SARS-CoV-2 (N) immunoassay. Because antibody responses

are impaired following PCR-confirmed natural infection we set a threshold of 0·25 times the cut-off

index (COI) at or above which patients were deemed to have had prior infection.[11] We defined a

second threshold of 0·12 times the COI, below which patients were deemed to have no evidence of

prior infection. Patients with a PCR test confirming SARS-CoV-2 infection at any time prior to

vaccination were deemed to have evidence of past infection irrespective of any antibody test result.

Outcomes

Our primary outcome was anti-SARS-CoV-2 anti-spike (S) protein receptor-binding protein antibodies

three to ten weeks after primary vaccination.

Secondary outcomes were:

(i) proportion of participants with seroconversion, defined by a threshold which has been

associated with pseudoneutralisation in vitro.

(ii) antibody concentrations and seroconversion in patients with PCR or serological evidence

of past SARS-CoV-2 infection at, or prior, to the post-vaccination serum sample.

(iii) antibody concentrations and seroconversion after two doses of vaccine.

Statistical Analysis

The sample size for CLARITY IBD was based on the number of participants required to demonstrate a

difference in the impact of infliximab and vedolizumab on seroprevalence and seroconversion

following SARS-CoV-2 infection, with an estimated background seroprevalence of 0·05. We

calculated that a sample of 6970 patients would provide 80% power to detect differences in the

seroprevalence of anti-SARS-CoV-2 antibodies in infliximab- compared with vedolizumab-treated

patients, whilst controlling for immunomodulator status at the 0·05 significance level. We stored and

then analysed all serum samples as soon as the Roche Elecsys anti-SARS-CoV-2 (S) immunoassay was

established in our laboratory.

Statistical analyses were undertaken in R 4·0·4 (R Foundation for Statistical Computing, Vienna,

Austria). All tests were two tailed and p-values <0·05 were considered significant. We included

patients with missing clinical data in analyses for which they had data and have specified the

denominator for each variable. Anti-S antibody concentrations are reported as geometric means and

standard deviations. Other continuous data are reported as median and interquartile range, and

discrete data as numbers and percentages, unless otherwise stated.

Univariable analyses, using t-tests of log-transformed anti-SARS-CoV-2 (S) antibody concentration

and Spearman's rank correlation coefficients, were used to identify demographic, disease, vaccine,

and treatment-related factors associated with the concentration of anti-SARS-CoV-2 (S) antibodies.

To test our primary outcome, we used multivariable linear regression models to identify factors

independently associated with log anti-SARS-CoV-2 (S) levels. A priori, we included age, ethnicity,

biologic medication, and immunomodulator use. No stepwise regression was performed. Results are

presented after exponentiation, so that the coefficients of the model correspond to the fold change

associated with each binary covariate. For age, a cut-off was chosen based on graphical inspection of

the relationship between age and anti-SARS-CoV-2 (S) antibody concentrations. We also report the

proportions of patients who seroconverted following vaccination. Seroconversion was defined by an

optimized cut-off of 15 U/mL, with a positive predictive value of 99·1%, based on the correlation

between receptor-binding domain antibodies and the cPass SARS-CoV-2 surrogate virus

neutralisation test (internal data, Roche Diagnostics GmbH, Germany).[15,16] We conducted sensitivity

analyses to compare antibody responses stratified by participants with serological or PCR evidence

of SARS-CoV-2 infection at any time prior to vaccination and in those who had received 2 doses of

vaccine.

Role of the funding source

CLARITY IBD is an investigator-led, UK National Institute for Health Research COVID-19 urgent public

health study, funded by the Royal Devon and Exeter NHS Foundation Trust, Hull University Teaching

Hospital NHS Trust, and by unrestricted educational grants from F. Hoffmann-La Roche AG

(Switzerland), Biogen GmbH (Switzerland), Celltrion Healthcare (South Korea) and Galapagos NV

(Belgium). None of our funding bodies had any role in study design, data collection or analysis,

writing, or decision to submit for publication.

Results

Between September 22nd 2020 and December 23rd 2020, 7226 patients were recruited to the

CLARITY study from 92 UK hospitals.[11] For the primary immunogenicity analyses we included 865

infliximab- and 428 vedolizumab-treated participants without evidence of prior SARS-CoV-2

infection, who had received uninterrupted biologic therapy since recruitment and had an antibody

test between 21 and 70 days after primary vaccination. Participant characteristics are shown in Table

1.

Anti-SARS-CoV-2 (S) antibody level following primary COVID-19 vaccine

Geometric mean [geometric SD] anti-SARS-CoV-2 (S) antibody concentrations were lower in patients

treated with infliximab than vedolizumab, following both the BNT162b2 (6·0 U/mL [5·9] vs 28·8

U/mL [5·4] P<0·0001) and ChAdOx1 nCoV-19 (4·7 U/mL [4·9] vs 13·8 U/mL [5·9] P<0·0001) vaccines

(Figure 1). Amongst infliximab-treated patients, the geometric mean [geometric SD] anti-SARS-CoV-2

(S) antibody concentrations were also lower in patients treated with a concomitant

immunomodulator. Additional univariable analyses are shown in Table 2.

In our multivariable models, anti-SARS-CoV-2 antibody concentrations were lower in infliximab-

compared with vedolizumab-treated patients in participants who received the BNT162b2 (fold

change [FC] 0·29 [95% CI 0·21, 0·40], p<0·0001) and ChAdOx1 nCoV-19 [FC] 0·39 [95% CI 0·30, 0·51],

p<0·0001) vaccines. Age ≥ 60 years, immunomodulator use, and current smoking were also

independently associated with lower anti-SARS-CoV-2 antibody concentrations in participants who

received either vaccine. Conversely, non-white ethnicity was associated with higher antibody

concentrations following both vaccines (figure 2).

The 15-day rolling geometric mean of anti-SARS-CoV-2 antibody concentrations are shown in

Figure 3. Three weeks after vaccination, we observed lower anti-SARS-CoV-2 (S) antibody

concentrations in infliximab- compared to vedolizumab-treated patients following both vaccines.

Sustained serological responses were observed in the vedolizumab- but not infliximab-treated

patients.

Seroconversion following primary COVID-19 vaccination

The lowest rates of seroconversion were observed in participants treated with infliximab in

combination with an immunomodulator with both the BNT162b2 (27.1%; 65/240) or ChAdOx1

nCoV-19 (20.2%; 60/297) vaccines. Highest rates of seroconversion were seen in patients treated

with vedolizumab monotherapy who received the BNT162b2 (74.7%;124/166) or ChAdOx1 nCoV-19

(57.3%; 94/164) vaccines (Figure 4).

Antibody responses following prior SARS-CoV-2 infection and two COVID-19 vaccine doses

Amongst participants with SARS-CoV-2 infection prior to vaccination, geometric mean [SD] anti-

SARS-CoV-2 (S) antibody concentrations were lower in infliximab- compared with vedolizumab-

treated patients in those who received a single-dose of BNT162b2 (191 U/mL [12·5] vs 1865 U/mL

[8·0] P<0·0001) and ChAdOx1 nCoV-19 (185 U/mL [9·3] vs 752 [12·5] P=0·046) vaccines. In both

infliximab- and vedolizumab-treated patients, antibody concentrations following vaccination were

higher than those observed in patients without prior infection (Figure 5). Overall, across both

vaccines, 82% (76/93) patients treated with infliximab and 97% (33/34) patients treated with

vedolizumab seroconverted (p=0·041).

Antibody responses were assessed in 27 patients following two doses of the BNT162b2 vaccine

without serological evidence of prior infection (Figure 5). In both infliximab- and vedolizumab-

treated patients, antibody levels and seroconversion rates were higher after two doses than after a

primary vaccine without prior infection (geometric means infliximab 158 U/mL [7·0] vs 6·0 U/mL

[5·9], p<0·0001; vedolizumab 562 U/mL [11·5] vs 28·8 U/mL [5·4], p = 0·018). After second-vaccine

doses 85% (17/20) infliximab- and 86% (6/7) vedolizumab-treated patients seroconverted (p=0·68).

Discussion

Key results

We have shown that anti-SARS-CoV-2 spike antibody levels and rates of seroconversion are lower

following vaccination with a single-dose of either BNT162b2 or ChAdOx1 nCoV-19 vaccines in

patients with IBD treated with infliximab than vedolizumab. Combination therapy with an

immunomodulator further attenuated immunogenicity to both vaccines in infliximab-treated

patients. Reassuringly, however, a second exposure to antigen, either by vaccination after infection,

or a second dose of vaccine led to seroconversion in most patients.

Direct comparisons between our data and the antibody responses reported in the vaccine

registration trials are limited by differences in the assays used to define immunogenicity and the

adoption of different thresholds to define seroconversion. No adequately powered studies have

reported the effect of anti-TNF drugs on vaccine responses.[17] Our findings are similar, however, to

recent reports of the immunogenicity of the BNT162b2 and mRNA-1273 vaccines in transplant

recipients and in patients with malignancy treated with anti-metabolite immunosuppression,

conventional chemotherapy or immune checkpoint inhibitors.[18,19] The authors showed fewer

patients treated with potent immunosuppressants seroconverted than healthy controls.

Importantly, as we have also shown here, second vaccine doses led to seroconversion in the cancer

cohort. However, even after two antigen exposures, a small subset of patients (18% [20/113]

infliximab-treated patients and 5% [2/41] vedolizumab-treated patients) in our study failed to mount

an antibody response. To identify this group, and because the sustainability of antibody responses

overall is unknown, serial measurement of antibody responses are indicated.

Urgent research is needed to understand the factors linked to non-response and how to potentiate

long-term immunogenicity in this group. Strategies to be tested include the manipulation of timing

of second vaccinations of second vaccinations, booster doses, the use of adjuvants and/or switching

between vaccines with different mechanisms of action. Moreover, from the public health

standpoint, recent case reports have shown that potent immunosuppression leads to chronic

nasopharyngeal carriage and evolution of new SARS-CoV-2 variants.[20,21] Whether this occurs in

patients treated with anti-TNF therapy with impaired antibody response is an important conceptual

concern.

Our data has other important findings relating to SARS-CoV-2 vaccine responses. We have

demonstrated that antibody responses to SARS-CoV-2 vaccines are reduced in older individuals and

current smokers. Smoking has also been associated with lower antibody responses to hepatitis B

vaccination and faster decay of antibodies after vaccination with live attenuated and trivalent

influenza vaccines.[22,23] We have also demonstrated higher antibody responses to both the BNT162b2

and ChAdOx1 nCoV-19 vaccines in non-white participants. This might be explained by differences in

genetics,[24] gut microbiota,[25] nutrition,[26] and priming of the immune system by prior exposure to

SARS-CoV-2 not detected by our pre-vaccination antibody test. Lower antibody concentrations were

also observed in patients with Crohn's disease when compared to patients with ulcerative colitis or

IBD-unclassified. Despite evidence of defective mucosal immunity, previous vaccine studies involving

patients with Crohn's disease or ulcerative colitis have not shown attenuated antibody responses to

vaccination in the absence of concomitant immunomodulator or biologic therapy.[6,7]

The cytokine TNF shapes multiple aspects of host immune responses, including T-cell dependent

antibody production. Genetic ablation of TNF results in disruption of B-cell follicles in germinal

centres with defective induction of antigen-induced antibody production.[27,28] These biological

properties may in part explain why TNF blockade is clinically beneficial in IMIDs, but also explain the

increased risk of serious and opportunistic infections and impaired response to other vaccines.

Whilst our data are biologically plausible, we acknowledge the following limitations of our study. We

have used an electrochemiluminescence immunoassay to measure antibody concentrations rather

than using a neutralising assay. Although neutralisation assays are considered more biologically

relevant, it is now established that anti receptor-binding domain antibodies, which target the spike

protein component that engages host cells through ligation of angiotensin-converting enzyme 2,

closely correlate with neutralisation assays.[29,30] Second, we only assessed humoral responses to

infection, and it is likely that protective immunity additionally requires induction of memory T cell

responses. Finally, we investigated one anti-TNF drug, infliximab, only. However, we suspect that our

key findings will apply to other anti-TNF biologics used to treat IMIDs, including adalimumab,

certolizumab, golimumab, and etanercept. Further observational data will be required to elucidate

the impact of other classes of therapies for IMIDs on SARS-CoV-2 vaccine immunogenicity.

Our findings have important implications for patients treated with anti-TNF drugs particularly those

also treated with an immunomodulator. Poor antibody responses to a single-dose of vaccine

unnecessarily exposes infliximab-treated patients to SARS-CoV-2 infection. However, because we

observed higher rates of seroconversion in patients with two exposures to SARS-CoV-2 antigen, even

in the presence of TNF blockade, these patients should be prioritised for optimally timed second

doses.   Until patients receive a second dose of vaccine they should consider that they are not

protected from SARS-CoV-2 infection and continue to practice enhanced physical distancing and

shielding if appropriate.

Conclusion

Infliximab is associated with attenuated immunogenicity to a single-dose of the BNT162b2 and

ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with inflammatory bowel disease.

Immunomodulators further blunted immunogenicity rates to both vaccines. Reassuringly,

vaccination after infection, or a second dose of vaccine led to seroconversion in most patients.

Delayed second dosing should be avoided in patients treated with infliximab.

Table 1: Baseline characteristics of participants who had anti-SARS-CoV-2 spike antibodies
measured 3 to 10 weeks following primary vaccination against SARS-CoV-2

Variable		Infliximab	Vedolizumab	Overall	p
Vaccine	BNT162b2	44·7% (387/865)	47·2% (202/428)	45·6% (589/1293)	0·41
	ChAdOx1 nCoV-19	55·3% (478/865)	52·8% (226/428)	54·4% (704/1293)	
Age (years)		41·4 (31·5 - 54·8)	49·6 (37·1 - 63·8)	43·8 (32·8 - 57·6)	<0·0001
Sex	Female	50·3% (434/863)	47·1% (200/425)	49·2% (634/1288)	0·19
	Male	49·7% (429/863)	52·7% (224/425)	50·7% (653/1288)	
	Intersex	0·0% (0/863)	0·0% (0/425)	0·0% (0/1288)	
	Prefer not to say	0·0% (0/863)	0·2% (1/425)	0·1% (1/1288)	
Ethnicity	White	91·8% (791/862)	89·9% (381/424)	91·1% (1172/1286)	0·62
	Asian	5·3% (46/862)	7·5% (32/424)	6·1% (78/1286)	
	Mixed	1·9% (16/862)	1·9% (8/424)	1·9% (24/1286)	
	Black	0·7% (6/862)	0·5% (2/424)	0·6% (8/1286)	
	Other	0·3% (3/862)	0·2% (1/424)	0·3% (4/1286)	
Diagnosis	Crohn's disease	65·4% (566/865)	40·7% (174/428)	57·2% (740/1293)	0·00050
	Ulcerative colitis or IBD-unclassified	34·6% (299/865)	59·3% (254/428)	42.8% (553/1293)	
Duration of IBD (years)		8·0 (4·0 - 16·0)	10·0 (5·0 - 17·8)	9·0 (4·0 - 16·0)	0·0040
Age at IBD diagnosis (years)		28·8 (21·6 - 41·8)	34·0 (23·3 - 47·6)	30·3 (21·9 - 43·7)	<0·0001
Immunomodulator		61·6% (533/865)	22·0% (94/427)	48·5% (627/1292)	<0·0001
5-ASA		23·0% (199/865)	31·6% (135/427)	25·9% (334/1292)	0·0012
Steroids		3·0% (26/865)	8·4% (36/427)	4·8% (62/1292)	<0·0001
BMI (kg/m^2)		25·9 (22·8 - 30·6)	26·1 (23·1 - 30·1)	26·0 (22·9 - 30·4)	0·75
Heart disease		3·6% (31/865)	6·5% (28/428)	4·6% (59/1293)	0·023
Diabetes		3·8% (33/865)	7·5% (32/428)	5·0% (65/1293)	0·0065
Lung disease		13·5% (117/865)	18·2% (78/428)	15·1% (195/1293)	0·032
Kidney disease		1·2% (10/865)	2·1% (9/428)	1·5% (19/1293)	0·22
Cancer		0·5% (4/865)	2·1% (9/428)	1·0% (13/1293)	0·013
Smoker	Yes	9·7% (84/862)	5·4% (23/425)	8·3% (107/1287)	0·0010
	Not currently	32·0% (276/862)	41·6% (177/425)	35·2% (453/1287)	
	Never	58·2% (502/862)	52·9% (225/425)	56·5% (727/1287)	
Exposure to documented cases of COVID-19		9·4% (81/862)	8·7% (37/425)	9·2% (118/1287)	0·76
Income deprivation score		0·086 (0·052 - 0·151)	0·084 (0·054 - 0·141)	0·086 (0·052 - 0·147)	0·94
Active disease (PRO2)		4·9% (41/831)	11·4% (46/405)	7·0% (87/1236)	<0·0001

353
354 **Abbreviations:** IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; BMI = Body Mass
355 Index; PRO2 = IBD disease activity. Values presented are median (interquartile range) or percentage
356 (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or
357 Fisher's exact test.

Table 2: Univariable associations with anti-SARS-CoV-2 spike antibodies, stratified by vaccine type

Variable		BNT162b2		ChAdOx1 nCoV-19	
		Value	p	Value	p
Biologic treatment	Infliximab	6·0 (5·9)	<0·0001	4·7 (4·9)	<0·0001
	Vedolizumab	28·8 (5·4)		13·8 (5·9)	
Immunomodulator in infliximab-treated participants	No	9·7 (4·7)	<0·0001	5·7 (5·1)	0·045
	Yes	4·4 (6·3)		4·2 (4·7)	
Immunomodulator in vedolizumab-treated participants	No	32·4 (5·2)	0·052	15·6 (6·0)	0·082
	Yes	16·7 (6·3)		10·0 (5·5)	
Age (years)		rho = -0·22	<0·0001	rho = -0·15	<0·0001
Sex	Female	9·4 (7·0)	0·092	6·6 (5·5)	0·83
	Male	10·9 (6·3)		6·8 (5·7)	
Ethnicity	White	9·4 (6·6)	0·037	6·2 (5·6)	0·0051
	Asian	20·9 (7·3)		16·1 (5·2)	
	Mixed	25·7 (6·7)		13·7 (5·3)	
	Black	12·5 (1·6)		19·4 (2·2)	
	Other	22·9 (3·7)		5·7 (3·1)	
Diagnosis	Crohn's disease	7·3 (6·4)	<0·0001	5·6 (5·6)	0·0014
	Ulcerative colitis or IBD-unclassified	15·6 (6·5)		8·5 (5·5)	
Duration of IBD (years)		rho = -0·16	<0·0001	rho = -0·12	0·0013
Age at IBD diagnosis (years)		rho = -0·13	0·0021	rho = -0·04	0·25
5-ASA	No	9·8 (6·6)	0·40	6·7 (5·5)	0·93
	Yes	11·5 (7·1)		6·6 (5·9)	
Steroids	No	10·2 (6·7)	0·90	6·8 (5·5)	0·12
	Yes	10·7 (7·3)		4·1 (6·7)	
BMI (kg/m^2)		rho = -0·08	0·068	rho = -0·01	0·81
Heart disease	No	10·3 (6·7)	0·65	6·9 (5·6)	0·010
	Yes	8·7 (7·0)		2·8 (5·2)	
Diabetes	No	10·7 (6·7)	0·0028	6·8 (5·6)	0·066
	Yes	4·1 (4·6)		4·0 (5·2)	
Lung disease	No	10·1 (6·9)	0·70	6·9 (5·5)	0·31
	Yes	10·9 (5·7)		5·7 (6·1)	
Kidney disease	No	10·2 (6·6)	0·60	6·7 (5·5)	0·66
	Yes	15·6 (10·4)		4·7 (12·4)	
Cancer	No	10·4 (6·6)	0·13	6·7 (5·6)	0·069
	Yes	2·0 (9·2)		2·3 (3·6)	
Smoking	Yes	4·7 (7·1)	0·0077	3·4 (4·8)	0·00077
	Not currently	9·4 (6·6)		6·1 (5·4)	
	Never	11·8 (6·5)		8·0 (5·7)	
Exposure to documented cases of COVID-19	No	10·3 (6·7)	0·87	6·6 (5·5)	0·53
	Yes	9·8 (6·8)		7·8 (6·1)	
Income deprivation score		rho = 0·01	0·75	rho = 0·02	0·65
Active disease (PRO2)	No	10·1 (6·5)	0·32	6·6 (5·4)	0·51
	Yes	14·0 (7·6)		8·1 (7·0)	

Abbreviations: IBD = inflammatory bowel disease; 5-ASA = 5-aminosalicylic acid; VAS = visual analogue scale. Values presented are geometric mean antibody concentration (geometric standard deviation) or Spearman's rho. P values represent the results of an unpaired t test or test of Spearman's rho.

Figure Captions

Figure 1: Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs

vedolizumab) and type of vaccine. The wider bar represents the geometric mean, while the narrower

bars are drawn one geometric standard deviation either side of the geometric mean. The threshold

shown of 15 U/mL is the one used to determine seroconversion.

Figure 2: Exponentiated coefficients of linear regression models of log(anti-SARS-CoV-2 spike

antibody concentration). The resultant values represent the fold change of antibody concentration

associated with each variable. Each vaccine was modelled separately, and then a further model was

created using all of the available data.

Figure 3: Rolling geometric mean antibody concentration over time stratified by biologic therapy

(infliximab vs vedolizumab) and vaccine. Geometric means are calculated using a rolling 15 day

window (i.e. 7 days either side of the day indicated). The shaded areas represent the 95% confidence

intervals of the geometric means. Overall, data from 2126 participants (1427 on infliximab and 699

on vedolizumab) are included in this graph between 1 and 63 days post vaccination.

Figure 4: Percentages of participants with seroconversion defined by an anti-SARS-CoV-2 spike

antibody concentration ≥ 15 U/mL, stratified by vaccine, biologic and immunomodulator use. Error

bars represent the 95% confidence interval of the percentages. **Abbreviations**: IMM =

immunomodulator

Figure 5: Anti-SARS-CoV-2 spike antibody concentration stratified by biologic therapy (infliximab vs

vedolizumab), prior infection, number of doses and type of vaccine. The wider bar represents the

geometric mean, while the narrower bars are drawn one geometric standard deviation either side of

the geometric mean. The threshold shown of 15 U/mL is the one used to determine seroconversion.

Contributions

NAK, JRG, CB, SS, NP, TA participated in the conception and design of this study. CB was the project manager and coordinated patient recruitment. RN and TJM coordinated all biochemical analyses and central laboratory aspects of the project. NAK, SL, JRG, NC, BH, DC, JRF, AF, PMI, NK, KBK, CAL, JM, SJM, RCGP, TR, PJS, AMV, TJM, SS, CWL, NP, TA were involved in the acquisition, analysis, or interpretation of data. Data analysis was done by NAK. Drafting of the manuscript was done by NAK, SL, JRG, NC, RN, DC, RCGP, SS, CWL, NP, TA. SS, NP and TA obtained the funding for the study. All the authors contributed to the critical review and final approval of the manuscript. NAK and TA have verified the underlying data.

Declarations of interest

personal fees from Gilead, personal fees from Abbvie, personal fees from Janssen, personal fees

from Boehringer Ingelheim, personal fees from Topivert, personal fees from VH2, personal fees from

Celgene, personal fees from Arena, personal fees from Samsung Bioepis, personal fees from Sandoz,

personal fees from Procise, personal fees from Prometheus, outside the submitted work. Dr.

Kamperidis reports personal fees from Janssen, outside the submitted work. Dr. Kok reports

personal fees from Janssen, personal fees from Takeda, personal fees from PredictImmune, personal

fees from Amgen, outside the submitted work. Dr. Lamb reports grants from Genentech, grants and

personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie, personal

fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from UCB

Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ, personal

fees from Dr Falk Pharma, grants from AstraZeneca, outside the submitted work. Dr. Macdonald

reports grants and personal fees from Takeda Pharmaceuticals, grants and personal fees from

Biogen, personal fees and non-financial support from AbbVie, personal fees from Grifols, personal

fees from Sandoz, personal fees from Celltrion, personal fees and non-financial support from

Janssen, personal fees from Vifor Pharmaceuticals, personal fees from Predictimmune, personal fees

from Bristol Myers Squibb, non-financial support from Ferring Pharmaceuticals, outside the

submitted work. Prof. Pollok reports acting as consultant, advisory board member, speaker or

recipient of educational grant from Dr Falk, Ferring, Janssen, Pharmacosmos and Takeda. Dr. Raine

reports grants and personal fees from Abbvie, personal fees from BMS, personal fees from Celgene,

personal fees from Ferring, personal fees from Gilead, personal fees from GSK, personal fees from

LabGenius, personal fees from Janssen, personal fees from Mylan, personal fees from MSD, personal

fees from Novartis, personal fees from Pfizer, personal fees from Sandoz, personal fees from Takeda,

personal fees from Galapagos, personal fees from Arena, outside the submitted work. Dr Smith

reports speaker fees and advisory board sponsorship from Janssen, Celltrion and Takeda outside the

submitted work. Dr. Verma reports personal fees and non-financial support from Takeda, personal

Infliximab and immunomodulators reduce immunogenicity of a single-dose of SARS-CoV-2 vaccines

Acknowledgements

CLARITY IBD is a UK National Institute for Health Research (NIHR) Urgent Public Health Study. The

NIHR Clinical Research Network supported study set-up, site identification, and delivery of this study.

This was facilitated by Professor Mark Hull, the National speciality lead for Gastroenterology. We

acknowledge the contribution of our Patient Advisory Group who helped shape the trial design

around patient priorities. Our partners, Crohn's and Colitis UK (CCUK), continue to support this

group and participate in Study Management Team meetings. We thank Professor Danny Altmann,

Professor Rosemary Boyton, Professor Graham Cooke and Dr Katrina Pollock for their helpful

discussions and review of the data. Laboratory tests were undertaken by the Exeter Blood Sciences

Laboratory at the Royal Devon and Exeter NHS Foundation Trust. The Exeter NIHR Clinical Research

Facility coordinated sample storage and management. Tariq Malik and James Thomas from Public

Health England, Guy Stevens, Katie Donelon, Elen de Lacy from Public Health Wales and Johanna

Bruce from Public Health Scotland supported linkage of central SARS-CoV-2 PCR test results with

study data. Roche Diagnostics Limited provided the Elecsys Anti-SARS-CoV-2 immunoassay for the

study. SL is supported by a Wellcome GW4-CAT fellowship. NC acknowledges support from CCUK.

CAL acknowledges support from the NIHR Newcastle Biomedical Research Centre and the support of

the Programmed Investigation Unit at Royal Victoria Infirmary, Newcastle upon Tyne. TR

acknowledges support with recruitment from the NIHR Cambridge BRC. CWL is funded by a UKRI

Future Leaders Fellowship. NP is supported by the NIHR Imperial Biomedical Research Center (BRC).

We acknowledge the study co-ordinators of the Exeter Inflammatory Bowel Disease Research Group:

Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative support to the study.

The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust.

Patient involvement

We conducted an electronic survey to gauge the opinion of patients with IBD on the patient

questionnaires to be delivered as part of the CLARITY IBD study. We surveyed 250 patients across 74

hospitals. All our proposed questions for study inclusion were rated as important or very important

by at least 83% of participants. The Exeter IBD Patient Panel refined the questions included in the

study questionnaire, reviewed the study protocol, supported the writing of the patient information

sheets, and participated in testing of the electronic consent form and patient questionnaire. A

member of the Exeter IBD Patient Panel sits on the study management committee, ensuring patient

involvement in all aspects of study delivery, data analysis and dissemination of findings.

Data sharing

The study protocol including the statistical analysis plan is available at www.clarityibd.org. Individual

participant de-identified data that underlie the results reported in this article will be available

immediately after publication for a period of 5 years. The data will be made available to investigators

whose proposed use of the data has been approved by an independent review committee. Analyses

will be restricted to the aims in the approved proposal. Proposals should be directed to

tariq.ahmad1@nhs.net. To gain access data requestors will need to sign a data access agreement.

References

Joint Committee on Vaccination and Immunisation. Optimising the COVID-19 vaccination programme for maximum short-term impact. 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact (accessed March 20, 2021).

European Centre for Disease Prevention and Control. Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA. 2021.

National Advisory Committee on Immunization. COVID-19 vaccine extended dose interval for Canadians. 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html (accessed March 22, 2021).

Jones GR, Lyons M, Plevris N, *et al.* IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. *Gut* 2019; **68**: 1953–60.

Hamilton B, Green H, Heerasing N, *et al.* Incidence and prevalence of inflammatory bowel disease in Devon, UK. *Frontline Gastroenterol* 2020; published online June 24. DOI:10.1136/flgastro-2019-101369.

Melmed GY, Agarwal N, Frenck RW, *et al.* Immunosuppression Impairs Response to Pneumococcal Polysaccharide Vaccination in Patients With Inflammatory Bowel Disease. *Am J Gastroenterol* 2010; **105**: 148–54.

Caldera F, Hillman L, Saha S, *et al.* Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial. *Inflamm Bowel Dis* 2019; **26**: 593–602.

Pratt PK, David N, Weber HC, *et al.* Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients with Inflammatory Bowel Disease on Infliximab Therapy. *Inflamm Bowel Dis* 2018; **24**: 380–6.

Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. *Am J Gastroenterol* 2013; **108**: 240–8.

Harrington JE, Hamilton RE, Ganley-Leal L, Farraye FA, Wasan SK. The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab. *Crohn's Colitis 360* 2020; **2**. DOI:10.1093/crocol/otaa082.

Kennedy NA, Goodhand JR, Bewshea C, *et al.* Inflammatory bowel disease Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. *Gut* 2021; **0**: 1–11.

Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international community of software platform partners. J. Biomed. Inform. 2019; **95**. DOI:10.1016/j.jbi.2019.103208.

Roche Diagnostics GmbH. Elecsys® Anti-SARS-CoV-2 S assay method sheet. 2020. https://diagnostics.roche.com/gb/en/products/params/elecsys-anti-sars-cov-2-s.html (accessed March 24, 2021).

Muench P, Jochum S, Wenderoth V, *et al.* Development and validation of the elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. *J Clin Microbiol* 2020; **58**: 1694–714.

Rubio-Acero R, Castelletti N, Fingerle V, *et al.* In search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patients. *medRxiv* 2021; : 2021.02.19.21252080.

L'Huillier AG, Meyer B, Andrey DO, *et al.* Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin*

Microbiol Infect 2021; **0**. DOI:10.1016/j.cmi.2021.01.005.

17   Alexander JL, Moran GW, Gaya DR, *et al.* SARS-CoV-2 vaccination for patients with
inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel
Disease section and IBD Clinical Research Group position statement. *Lancet Gastroenterol*
Hepatol 2021; **6**: 218–24.

18   Boyarsky BJ, Werbel WA, Avery RK, *et al.* Immunogenicity of a Single Dose of SARS-CoV-2
Messenger RNA Vaccine in Solid Organ Transplant Recipients. *JAMA* 2021; published online
March 15. DOI:10.1001/jama.2021.4385.

19   Monin-Aldama L, Laing AG, McKenzie DR, *et al.* Interim results of the safety and immune-
efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context
of the UK vaccine priority guidelines. *medRxiv* 2021; : 2021.03.17.21253131.

20   Choi B, Choudhary MC, Regan J, *et al.* Persistence and Evolution of SARS-CoV-2 in an
Immunocompromised Host. *N Engl J Med* 2020; **383**: 2291–3.

21   Avanzato VA, Matson MJ, Seifert SN, *et al.* Case Study: Prolonged Infectious SARS-CoV-2
Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell* 2020;
183: 1901-1912.e9.

22   Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on
immunological responses to hepatitis B vaccine. *Vaccine* 1994; **12**: 771–2.

23   MacKenzie JS, MacKenzie IH, Holt PG. The effect of cigarette smoking on susceptibility to
epidemic influenza and on serological responses to live attenuated and killed subunit
influenza vaccines. *J Hyg (Lond)* 1976; **77**: 409–17.

24   Haralambieva IH, Ovsyannikova IG, Umlauf BJ, *et al.* Genetic polymorphisms in host antiviral
genes: Associations with humoral and cellular immunity to measles vaccine. *Vaccine* 2011;
29: 8988–97.

25   Huda MN, Lewis Z, Kalanetra KM, *et al.* Stool microbiota and vaccine responses of infants.
Pediatrics 2014; **134**: e362–72.

26   Savy M, Edmond K, Fine PEM, *et al.* Landscape analysis of interactions between nutrition and
vaccine responses in children. *J Nutr* 2009; **139**. DOI:10.3945/jn.109.105312.

27   Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in
TNFα-deficient mice: A critical requirement for TNFα in the formation of primary B cell
follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the
humoral immune response. *J Exp Med* 1996; **184**: 1397–411.

28   Ritter U, Meissner A, Ott J, Körner H. Analysis of the maturation process of dendritic cells
deficient for TNF and lymphotoxin-α reveals an essential role for TNF. *J Leukoc Biol* 2003; **74**:
216–22.

29   Marot S, Malet I, Leducq V, *et al.* Rapid decline of neutralizing antibodies against SARS-CoV-2
among infected healthcare workers. *Nat Commun* 2021; **12**: 1–7.

30   Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-
2 Variants After Infection and Vaccination. *JAMA* 2021; published online March 19.
DOI:10.1001/jama.2021.4388.

BNT162b2

Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	386/587		0·29 (0·21, 0·40)	<0·0001
Immunomodulator	269/587		0·41 (0·31, 0·55)	<0·0001
Crohn's disease (vs UC or IBDU)	327/587		0·75 (0·57, 1·00)	0·046
Age ≥ 60	113/587		0·34 (0·24, 0·47)	<0·0001
Non-white ethnicity	61/587		1·81 (1·16, 2·81)	0·0085
Current smoker	44/587		0·52 (0·31, 0·86)	0·011

0.2 0.5 1 2

ChAdOx1 nCoV-19

Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	475/697		0·39 (0·30, 0·51)	<0·0001
Immunomodulator	355/697		0·65 (0·50, 0·84)	0·00085
Crohn's disease (vs UC or IBDU)	409/697		0·85 (0·66, 1·09)	0·20
Age ≥ 60	162/697		0·48 (0·36, 0·65)	<0·0001
Non-white ethnicity	55/697		2·04 (1·31, 3·17)	0·0017
Current smoker	63/697		0·55 (0·36, 0·84)	0·0059

0.2 0.5 1 2

All

Variable	N		Fold change (95% CI)	p
Infliximab (vs vedolizumab)	861/1284		0·34 (0·27, 0·41)	<0·0001
Immunomodulator	624/1284		0·51 (0·42, 0·62)	<0·0001
Crohn's disease (vs UC or IBDU)	736/1284		0·79 (0·66, 0·96)	0·015
Age ≥ 60	275/1284		0·40 (0·32, 0·50)	<0·0001
Non-white ethnicity	116/1284		1·95 (1·43, 2·67)	<0·0001
Current smoker	107/1284		0·53 (0·39, 0·74)	0·00016

0.2 0.5 1 2